Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

NCT05924672 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT05924672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05924672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Ra-223 in PSMA PET Optimally Selected Patients
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 30, 2024
Completion date
March 31, 2027
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate carcinoma, metastatic malignant neoplasm in the bone, stage ivb prostate cancer ajcc v8